" class="no-js "lang="en-US"> BlueRock Therapeutics - Medtech Alert
Friday, April 19, 2024
BlueRock Therapeutics | Pharmtech Focus

BlueRock Therapeutics

About BlueRock Therapeutics

BlueRock Therapeutics

BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications. BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. The company strives to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine.

Related Story

BlueRock Therapeutics to use Rune Labs' Clinical Trial Platform to Better Characterize Parkinson's Disease State in Cell Therapy Trials

March 14 2023

Rune Labs, a precision neurology software and data platform company, today announced a partnership with […]

Bayer’s Bluerock Therapeutics Establishes European Site for Cell Therapy Innovation

June 9 2022

Bayer AG announced today that BlueRock Therapeutics LP (BlueRock), a clinical stage biopharmaceutical company and […]